Taking stock of the drug industry, from the lab to the medicine chestAugust 22, 2024Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Illustration: Alex Hogan/STAT; Photo: Eisai via AP STAT+ | U.K.'s cost-effectiveness agency gives negative review of Alzheimer's drug Leqembi The review from the U.K.'s cost-effectiveness watchdog means the Alzheimer's therapy wouldn't be available through the NHS. By Andrew Joseph STAT+ | Gene therapy pioneer Jim Wilson believes he can commercialize rare-disease drugs in a tough climate As other firms are 'walking away, we can lean into this,' Wilson tells STAT, discussing launch of Gemma Biotherapeutics and Franklin Biolabs By Jonathan Wosen FDA approves updated Covid-19 vaccines, shots should be available in days Pfizer and Moderna are set to begin shipping millions of doses. Novavax expects its updated vaccine version to be available a little later. By Associated Press Adobe STAT+ | Tome Biosciences, once a high-flying gene-editing startup, is floundering The company announced in December that it had raised $213 million to fund what it called the "final chapter in genomic medicines." By Jason Mast and Allison DeAngelis Opinion: In drug development, diversity must be extended to preclinical research The FDA's draft guidance on diversity in clinical trials is good, but it overlooks the lack of diversity in preclinical research. By Sophie Zaaijer More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2024, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments